PURPOSE: To evaluate the dosimetric and clinical outcomes of involved-field intensity-modulated radiotherapy (IF-IMRT) for patients with early-stage Hodgkin's lymphoma (HL) with mediastinal involvement. METHODS AND MATERIALS: Fifty-two patients with early-stage HL that involved the mediastinum were reviewed. Eight patients had Stage I disease, and 44 patients had Stage II disease. Twenty-three patients (44%) presented with a bulky mediastinum, whereas 42 patients (81%) had involvement of both the mediastinum and either cervical or axillary nodes. All patients received combination chemotherapy followed by IF-IMRT. The prescribed radiation dose was 30-40 Gy. The dose-volume histograms of the target volume and critical normal structures were evaluated. RESULTS: The median mean dose to the primary involved regions (planning target volume, PTV1) and boost area (PTV2) was 37.5 Gy and 42.1 Gy, respectively. Only 0.4% and 1.3% of the PTV1 and 0.1% and 0.5% of the PTV2 received less than 90% and 95% of the prescribed dose, indicating excellent PTV coverage. The median mean lung dose and V20 to the lungs were 13.8 Gy and 25.9%, respectively. The 3-year overall survival, local control, and progression-free survival rates were 100%, 97.9%, and 96%, respectively. No Grade 4 or 5 acute or late toxicities were reported. CONCLUSIONS: Despite the large target volume, IF-IMRT gave excellent dose coverage and a favorable prognosis, with mild toxicity in patients with early-stage mediastinal HL.
PURPOSE: To evaluate the dosimetric and clinical outcomes of involved-field intensity-modulated radiotherapy (IF-IMRT) for patients with early-stage Hodgkin's lymphoma (HL) with mediastinal involvement. METHODS AND MATERIALS: Fifty-two patients with early-stage HL that involved the mediastinum were reviewed. Eight patients had Stage I disease, and 44 patients had Stage II disease. Twenty-three patients (44%) presented with a bulky mediastinum, whereas 42 patients (81%) had involvement of both the mediastinum and either cervical or axillary nodes. All patients received combination chemotherapy followed by IF-IMRT. The prescribed radiation dose was 30-40 Gy. The dose-volume histograms of the target volume and critical normal structures were evaluated. RESULTS: The median mean dose to the primary involved regions (planning target volume, PTV1) and boost area (PTV2) was 37.5 Gy and 42.1 Gy, respectively. Only 0.4% and 1.3% of the PTV1 and 0.1% and 0.5% of the PTV2 received less than 90% and 95% of the prescribed dose, indicating excellent PTV coverage. The median mean lung dose and V20 to the lungs were 13.8 Gy and 25.9%, respectively. The 3-year overall survival, local control, and progression-free survival rates were 100%, 97.9%, and 96%, respectively. No Grade 4 or 5 acute or late toxicities were reported. CONCLUSIONS: Despite the large target volume, IF-IMRT gave excellent dose coverage and a favorable prognosis, with mild toxicity in patients with early-stage mediastinal HL.
Authors: Adjani A Peralta; Mark S Link; Joel Schwartz; Heike Luttmann-Gibson; Douglas W Dockery; Annelise Blomberg; Yaguang Wei; Murray A Mittleman; Diane R Gold; Francine Laden; Brent A Coull; Petros Koutrakis Journal: Circulation Date: 2020-06-30 Impact factor: 29.690
Authors: José Carlos Jaime-Pérez; Carmen Magdalena Gamboa-Alonso; José Ramón Padilla-Medina; Raúl Alberto Jiménez-Castillo; Leticia Alejandra Olguín-Ramírez; César Homero Gutiérrez-Aguirre; Olga Graciela Cantú-Rodríguez; David Gómez-Almaguer Journal: Rev Bras Hematol Hemoter Date: 2017-09-14
Authors: B S Hoppe; C E Hill-Kayser; Y D Tseng; S Flampouri; H M Elmongy; O Cahlon; N P Mendenhall; A Maity; L A McGee; J P Plastaras Journal: Ann Oncol Date: 2017-09-01 Impact factor: 32.976
Authors: Chelsea C Pinnix; Jinhai Huo; Sarah A Milgrom; Zeinab Abou Yehia; Michelle Fanale; Yasuhiro Oki; Bouthaina S Dabaja; Grace L Smith Journal: Adv Radiat Oncol Date: 2018-04-24